SCHEMBL1821353

SCHEMBL1821353

CN(c1ccccc1)C(Cl)C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.45
SLC6A4 P31645 4/20 0.45
ALDH1A1 P00352 4/20 0.40
POLB P06746 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
ALOX5 P09917 1/20 0.38
KMT2A Q03164 3/20 0.38
HTT P42858 2/20 0.38
MEN1 O00255 1/20 0.38
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
GLA P06280 1/20 0.37
TSHR P16473 1/20 0.37
PLAU P00749 1/20 0.36
HPGD P15428 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4589661 0.84 SLC6A2 (0.43) SLC6A2SLC6A4ALDH1A1POLBLMNA
SCHEMBL11762898 0.83 ALDH1A1 (0.42) SLC6A2SLC6A4ALDH1A1POLBHTT
SCHEMBL1818475 0.79 POLB (0.46) SLC6A2SLC6A4POLBLMNAKMT2A
SCHEMBL11765261 0.79 CA1 (0.46) SLC6A2SLC6A4ALDH1A1TP53SMN1; SMN2
SCHEMBL1821413 0.78 ALOX5 (0.43) SLC6A2SLC6A4ALDH1A1POLBLMNA
SCHEMBL8586520 0.78 ALOX5 (0.43) SLC6A2SLC6A4ALDH1A1POLBLMNA
SCHEMBL11760439 0.77 SLC6A2 (0.45) SLC6A2SLC6A4ALDH1A1POLBLMNA
SCHEMBL1818385 0.77 ALDH1A1 (0.46) SLC6A2SLC6A4ALDH1A1POLBLMNA
SCHEMBL11763140 0.77 ALDH1A1 (0.46) ALDH1A1POLBLMNATP53SMN1; SMN2
Carbamic Acid SCHEMBL27977071 0.76 ALDH1A1 (0.46) SLC6A2SLC6A4ALDH1A1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947712-B2 Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent WYETH LLC (US) 2011-05-24 US disclosed
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof WYETH (US) 2008-10-30 US disclosed
US-4023956-A Amide phosphorothiolate herbicides SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof MMP8, MMP26, MMP9 SLC6A2 3157/4885SLC6A4 3345/4885ALDH1A1 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.